Protean BioDiagnostics
Protean BioDiagnostics is focused on improving the care and outcome of cancer patients with our inno
There has been a revolution in treatment advances for patients with cancer. These include explosive development and use of both targeted therapy and immune based therapies. The most effective use of these new treatments require access to advanced tissue and blood diagnostics. Unfortunately many patients and oncologists cannot easily access these new diagnostics advances because they live in areas
14/03/2024
Here’s the latest from Curious Dr. George! Read “Protean BioDiagnostics: One Way to Access Full-Service Precision Oncology Testing” here: bit.ly/CCCDGProteanBioDx
The use of advanced molecular testing of various cancers over the last 10-15 years has driven development of the field of precision oncology. Now, many patients with a variety of cancer types can benefit from targeted therapies. However, accessing precision testing and treatment can be a major challenge. Our Curious Dr. George asks Anthony M. Magliocco, MD, Founder and CEO of Protean BioDiagnostics, how his company enables better access.
01/03/2024
We have just released a brand new episode of Cancer Informant, dedicated to the topic of clinical trials for cancer treatment. 🔎 Watch now on youtube: www.youtube.com/watch?v=kOxGOT5rkx0
Navigating Cancer Clinical Trials with Confidence In this video Dr. Magliocco explains why clinical trials are valuable for cancer patients, exploring their safety, how they work, and more.To ask us a questi...
01/01/2024
Happy New Year from Protean!
May the coming year be filled with boundless opportunities, good health, and new discoveries.
From all of us at Protean BioDiagnostics, warm wishes for a joyful holiday season filled with cherished moments. May this season bring you happiness, peace, and good health!
29/11/2023
22/11/2023
Happy Thanksgiving from everyone at Protean.
We hope you have a wonderful Thanksgiving with quality time to rejuvenate, reflect, gather, and celebrate.
03/11/2023
Protean's CEO Dr. Anthony Magliocco will be speaking at the Future of Cancer Care event in Tampa FL on November 9th.
Register for the event on their website: https://www.futurecancercare.com/agenda/
05/10/2023
Announcing Aventa FusionPlus, the first CLIA certified 3D genomics test for cancer patients. Aventa is a joint collaboration between Protean and Arima Genomics.
Learn more on our website: https://lnkd.in/e2jt3inj
06/07/2023
Reducing Your Cancer Risk - Cancer Prevention & Screening Cancer is increasing in incidence and prevalence. Cancer is the second most common cause of death, and is poised to become the main cause of death based on c...
Protean had the incredible opportunity to discuss barriers to cancer care in America and how Protean is helping close them at a recent town hall meeting.
We are thankful to Congressman Soto for the invitation!
10/05/2023
Spesana Announces Agreement with Protean BioDiagnostics to Advance Precision Medicine at the Point of Care Spesana, a company dedicated to improving patient care with an innovative, point of care precision medicine platform, has announced an agreement with Protean BioDiagnostics. This new agreement will amplify Protean's
07/05/2023
The Importance of a Second Opinion for a Cancer Diagnosis Learn about why a second opinion on your diagnosis is critical to the management of your cancer, on this episode of Cancer Informant podcast.To ask us a ques...
07/05/2023
Prostate Cancer: What You Need to Know In this episode of Cancer Informant, Dr. Magliocco covers what you need to know about prostate cancer. Topics covered include key treatments for prostate can...
06/05/2023
Subscribe to our new Cancer Informant you tube channel for all the latest updates in cancer research and treatments!
Cancer Informant - YouTube Cancer Informant is a podcast made to inform cancer patients and their loved ones about their options for cancer testing and treatment. Dr. Tony Magliocco is...
01/05/2023
How immunotherapy before surgery boosts systemic immunity in head and neck cancer | Center for Cancer Research New evidence uncovered by CCR researchers may explain why treating head and neck cancers with the immunotherapy checkpoint inhibitor drug bintrafusp alfa before surgery may be more effective at preventing disease recurrence than surgery alone. The results, which show that bintrafusp alfa increases t...
22/03/2023
Dr. Magliocco will be presenting at Future Genomics 2023!
Learn About:
- Implementing WES as part of the Protean MAPS™ system
- Clinical uses of multiplex IHC for analysis of PDL1 in cancer specimens
- And more!
Learn More: www.proteanbiodx.com/news/2023/futuregenomics
11/03/2023
What is precision oncology, and why do you need it? Learn more about what precision medicine is, and how it can help you in our full video: https://youtu.be/ZpGeK7l7vyE ...
11/03/2023
Sudden start up crisis triggered by shocking SVB collapse.
Silicon Valley Bank failure could wipe out 'a whole generation of startups' The implosion of Silicon Valley Bank could force hundreds of tech startups to lay off workers or shut down completely. It remains unclear how much, if any, of depositors' money will be returned.
08/03/2023
Colon & Re**al Cancer: What You Need to Know Colorectal cancer is becoming more common, but fortunately it is one of the more treatable and curable cancers. Topics covered include risk factors, signs & ...
23/02/2023
have a heightened risk of occupational and unusual cancers. Protean is determined to help with research, early detection, rapid cancer analysis and effective treatment matching.
Learn more at: https://lnkd.in/enj_8m_q.
18/02/2023
Listen to our latest episode, all about pancreatic neuroendocrine cancer out on YouTube, Spotify, and Apple Podcasts! https://youtu.be/cyWux5X2E-A
18/02/2023
Frustrated by the inaccuracy of clinical risk stratification for papillary thyroid cancer? Clinical risk stratification is 80% accurate. It’s time to make the change.
For more information on Thyroid GuidePx® email us at [email protected]
Happy Holidays from Protean!
Wishing everyone all the best in 2023.
17/11/2022
Thank you CorePath, it was amazing seeing your brand new facilities and meeting your talented team!
CorePath is an exceptional lab company that is providing services that help patients with cancer across the country.
04/11/2022
Dr. Anthony Magliocco from Protean BioDiagnostics will present data on the technical validation of Thyroid GuidePx® at the Association for Molecular Pathology (AMP) 2022 Annual Meeting and Expo. Come visit Poster on Friday, November 4, from 9:15 AM - 10:15 AM MT.
Thyroid GuidePx® is a new prognostic test for papillary thyroid cancer that will refine how thyroid surgeons and endocrinologists make treatment decisions. The Thyroid GuidePx® assay is capable of producing repeatable gene expression measures and enables reliable classification of molecular subtypes.
Thyroid GuidePx® was developed by Qualisure Diagnostics in Calgary, AB. The test is now available through Protean BioDiagnostics in Orlando, FL.
https://www.proteanbiodx.com/thyroidguidepx
Protean BioDiagnostics Association for Molecular Pathology (AMP) Annual Meeting and Expo
04/11/2022
Protean Presents on the Importance of in Uncovering a Patient's True Diagnosis at AMP 2022
Learn More: http://proteanbiodx.com/news/2022/amp22
03/11/2022
Our newest video episode of Cancer Informant is now available on youtube. In this episode we discuss benign breast conditions that might be mistaken for breast cancer. https://lnkd.in/gzHdT24y
We hope that you will watch, share and let us know if you have any questions or feedback!
10/10/2022
Bringing Precision Pathology Services to Community Practice Oncologists
Protean Biodiagnostics is a biotechnology company focused on developing and deploying the latest diagnostic tools and services to community based oncologists who are intent on providing their patients with the most advanced and effective personalized oncology care available. These products include PATHMAPS, an innovative “next generation” tissue analysis system including artificial intelligence enhancements, Risk MAPS, a comprehensive genetic and hereditary risk evaluation product, and liquid MAPS, the latest generation of liquid biopsy tools. Protean is taking a multiomic and data integration approach while at the same time making access efficient
Protean has developed all of the products with the patient oncologist team in mind. The goal is to provide advanced diagnostics when and where it is needed without distraction.
Videos (show all)
